Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
2
×
life sciences
national blog main
national top stories
san francisco blog main
alexion pharmaceuticals
alnylam pharmaceutials
arrowhead pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boehringer ingelheim
deals
dicerna pharmaceuticals
duchenne muscular dystrophy
dyne therapeutics
eli lilly
facioscapulohumeral muscular dystrophy
gene therapy
hepatitis b
indiana blog main
indiana top stories
johnson & johnson
joshua brumm
kaleido biosciences
muscular dystrophy
myotonic dystrophy type 1
neurodegenerative diseases
new york blog main
primary hyperoxaluria
rare disease drugs
rna interference
romesh subramanian
san diego blog main
What
ago
2
×
long
2
×
medicines
abandoning
baggage
biotechs
companies
considering
cuts
data
deal
development
dicerna
diseases
drug
dyne
early
expected
experimental
eyes
free
genetic
gets
having
humans
interference
ipo
ipos
muscle
pharma
rare
reach
rna
rnai
signs
small
therapeutics
wasn’t
worked
Language
unset
Current search:
ago
×
long
×
" clinical trials "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
